Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210

被引：35

作者：

Balar, Arjun Vasant

Dreicer, Robert

Loriot, Yohann

Perez-Gracia, Jose Luis

Hoffman-Censits, Jean H.

Petrylak, Daniel Peter

Van Der Heijden, Michiel Simon

Ding, Beiying

Shen, Xiaodong

Rosenberg, Jonathan E.

机构：

[1] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[2] Univ Virginia, Emily Couric Clin Canc Ctr, Charlottesville, VA USA

[3] Gustave Roussy, Villejuif, France

[4] Clin Univ Navarra, Pamplona, Spain

[5] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA

[6] Yale Univ, Sch Med, New Haven, CT USA

[7] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[8] Netherlands Canc Inst, Dept Med Oncol, San Francisco, CA USA

[9] Genentech Inc, San Francisco, CA 94080 USA

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4523

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4523

引用

页数：2